Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma
Authors:
Open Access
- 25 October 2023
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 26 (6) , 1-7
Abstract
Lenvatinib, a multi‑kinase inhibitor, serves a crucial role in the treatment of unresectable hepatocellular carcinoma (HCC). However, >50% of patients receiving lenvatinib therapy experience tumor growth or metastasis within 1 year, highlighting the need to address acquired resistance as a critical clinical challenge. To elucidate the factors associated with acquired resistance to lenvatinib, a lenvatinib‑resistant HCC cell line (JHH‑7_LR) was established by exposing a lenvatinib‑sensitive HCC cell line, JHH‑7, to lenvatinib. The changes in protein expression associated with the development of resistance were analyzed using a proteomic approach, detecting 1,321 proteins and significant changes in the expression of 267 proteins. Using Ingenuity Pathway Analysis bioinformatics software, it was revealed that the activity of multiple signaling pathways varied alongside the changes in expression of these proteins, and c‑SRC was identified as a protein involved in a number of these signaling pathways, with its activity varying markedly upon the acquisition of resistance. When co‑administering dasatinib, a c‑SRC inhibitor, the partial restoration of lenvatinib sensitivity in the JHH‑7_LR cell line was observed. The present study demonstrated that increased c‑SRC expression was partially associated with HCC resistance to lenvatinib, suggesting that c‑SRC inhibition could reduce the resistance of HCC to lenvatinib.Keywords
This publication has 50 references indexed in Scilit:
- Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cellsBMC Cancer, 2013
- Detection of Elevated Plasma Levels of Epidermal Growth Factor Receptor Before Breast Cancer Diagnosis among Hormone Therapy UsersCancer Research, 2010
- Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer PatientsCancer Epidemiology, Biomarkers & Prevention, 2010
- Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In VitroDigestive Diseases and Sciences, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- A renaissance for SRCNature Reviews Cancer, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Involvement of Src and Epidermal Growth Factor Receptor in the Signal-transducing Function of Na+/K+-ATPaseJournal of Biological Chemistry, 2000
- Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene productNature, 1980